skip to main content

Content language

Contact us: CRM@email.irandoc.ac.ir

Concept information

... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > lipid > sphingolipid > ceramide > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > pnictogen molecular entity > nitrogen molecular entity > organonitrogen compound > sphingolipid > ceramide > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)
... > organooxygen compound > sphingolipid > ceramide > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > pnictogen molecular entity > nitrogen molecular entity > organonitrogen compound > carboxamide > ceramide > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)
... > organooxygen compound > carboxamide > ceramide > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > pnictogen molecular entity > nitrogen molecular entity > amide > primary amide > carboxamide > ceramide > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > lipid > liposaccharide > glycolipid > glycosphingolipid > acidic glycosphingolipid > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)
... > organooxygen compound > carbohydrates and carbohydrate derivatives > carbohydrate derivative > liposaccharide > glycolipid > glycosphingolipid > acidic glycosphingolipid > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > lipid > sphingolipid > glycosphingolipid > acidic glycosphingolipid > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > pnictogen molecular entity > nitrogen molecular entity > organonitrogen compound > sphingolipid > glycosphingolipid > acidic glycosphingolipid > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)
... > organooxygen compound > sphingolipid > glycosphingolipid > acidic glycosphingolipid > ganglioside > sialotriaosylceramide > beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)

Preferred term

beta-galnac-(1->4)-[alpha-neu5ac-(2->8)-alpha-neu5ac-(2->8)-alpha-neu5ac-(2->3)]-beta-gal-(1->4)-beta-glc-(1->1')-cer(d18:1/16:0)  

Type

  • http://www.irandoc.ac.ir/onto/irandoc-meta/Concept

Broader concept

charge

  • 0

formula

  • C87H151N5O42

has_functional_parent

inchi

  • InChI=1S/C87H151N5O42/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-50(103)49(92-60(108)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)44-123-80-71(115)70(114)73(58(42-97)125-80)127-81-72(116)78(74(59(43-98)126-81)128-79-64(91-48(6)102)69(113)66(110)55(39-94)124-79)134-87(84(121)122)37-53(106)63(90-47(5)101)77(133-87)68(112)57(41-96)130-86(83(119)120)36-52(105)62(89-46(4)100)76(132-86)67(111)56(40-95)129-85(82(117)118)35-51(104)61(88-45(3)99)75(131-85)65(109)54(107)38-93/h31,33,49-59,61-81,93-98,103-107,109-116H,7-30,32,34-44H2,1-6H3,(H,88,99)(H,89,100)(H,90,101)(H,91,102)(H,92,108)(H,117,118)(H,119,120)(H,121,122)/b33-31+/t49-,50+,51-,52-,53-,54+,55+,56+,57+,58+,59+,61+,62+,63+,64+,65+,66-,67+,68+,69+,70+,71+,72+,73+,74-,75+,76+,77+,78+,79-,80+,81-,85+,86+,87-/m0/s1

inchikey

  • VEQIRBNQLSOJBN-WQAKHMPDSA-N

mass

  • 1939.13810

monoisotopicmass

  • 1937.98336

smiles

  • CCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@H](O)[C@@H](NC(C)=O)[C@@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@H](O)[C@@H](NC(C)=O)[C@@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@H](O)[C@@H](NC(C)=O)[C@@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)/C=C/CCCCCCCCCCCCC

subset

  • 3_STAR

synonym EXACT

  • (2S,3R,4E)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-en-1-yl (6R)-5-(acetylamino)-6-[(1S,2R)-2-({(6R)-5-(acetylamino)-6-[(1S,2R)-2-({(6R)-5-(acetylamino)-3,5-dideoxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]-beta-L-threo-hex-2-ulopyranonosyl}oxy)-1,3-dihydroxypropyl]-3,5-dideoxy-b-L-threo-hex-2-ulopyranonosyl}oxy)-1,3-dihydroxypropyl]-3,5-dideoxy-beta-L-threo-hex-2-ulopyranonosyl-(2->3)-[2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1->4)]-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranoside

URI

http://www.irandoc.acir/onto/irandoc/CHEBI:84653

Download this concept: